Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the recommended doses of selinexor in
combination with liposomal doxorubicin and dexamethasone for patients with relapsed and
refractory myeloma. In addition, the study will assess whether this combination with
effective for patients with multiple myeloma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute